2022 Fiscal Year Final Research Report
Development of biomarkers to predict the efficacy of anti-PD-1 antibody
Project/Area Number |
17K15498
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Medical pharmacy
|
Research Institution | Takasaki University of Health and Welfare (2019-2022) Gunma University (2017-2018) |
Principal Investigator |
Takahashi Yuta 高崎健康福祉大学, 薬学部, 助教 (70509918)
|
Project Period (FY) |
2017-04-01 – 2023-03-31
|
Keywords | 抗体医薬品 / 血中薬物濃度 / バイオマーカー |
Outline of Final Research Achievements |
Methods for analysing drug blood levels and searching for markers of drug efficacy and side effects were investigated to establish optimal dosing design methods for nivolumab, a high-cost antibody drug used for lung cancer. The drug blood levels of nivolumab can now be measured in a relatively simple method and samples from patients treated with nivolumab alone can be analysed. Peptides obtained by trypsin digestion of cancer-related proteins were analysed, and it was assessed that it was difficult to obtain markers by the usual method of serum proteomics due to insufficient sensitivity. Since the application for the Grant-in-Aid for Scientific Research for this study, several marker analyses for drug efficacy and side effects have been reported, and the relationship between these markers and blood levels of nivolumab is currently under investigation.
|
Free Research Field |
医療薬学
|
Academic Significance and Societal Importance of the Research Achievements |
肺癌に使用される高額な抗体医薬品であるニボルマブの薬物血中濃度や血中の特定のタンパク質と薬効もしくは副作用に関連が認められることにより、薬効や副作用の予測方法の検討が可能となる。ニボルマブの薬効や副作用の予測方法を見出すことができれば適正使用を図ることが可能となる。さらには同様の薬効群の医薬品においても同様の検討を行うことにより、薬効や副作用の予測方法の検討を実施することが可能となる。
|